Published in Cardiovascular Device Liability Week, August 3rd, 2008
In a research note on July 8th, Jesup & Lamont stated that the split is designed to improve the stock's marketability to institutional investors. As a result of the 1-for-10 reverse split, Siri is adjusting his price target from $2.00 per...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Device Liability Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.